Literature DB >> 19117774

Patient risk stratification using Gleason score concordance and upgrading among men with prostate biopsy Gleason score 6 or 7.

Faye B Serkin1, Douglas W Soderdahl, Jennifer Cullen, Yongmei Chen, Javier Hernandez.   

Abstract

PURPOSE: To define the impact of discordant Gleason sum (GS) between prostate biopsy (Pbx) tissue and radical prostatectomy (RP) specimen among men initially diagnosed with Gleason 6 or 7 prostate adenocarcinoma.
MATERIALS AND METHODS: We evaluated patients diagnosed with GS 6 or 7 and treated primarily with RP. We defined the frequency of GS discordance between Pbx and RP pathology reports. We analyzed pretreatment parameters associated with GS discordance and compared immediate postprostatectomy outcome variables across patient groups defined by their GS and concordance. We then conducted survival analysis for biochemical recurrence across patient groups defined by their GS and concordance status.
RESULTS: Among patients with GS 6 on Pbx, 681/1,847 (36.86%) patients were upgraded to GS 7 or higher after RP. Surgical margin, capsular involvement, seminal vesicle, and nodal involvement status were more favorable in patients with concordant Pbx and RP specimen with GS 6 (P < 0.0001). Patients with smaller transrectal ultrasound (TRUS) prostate volume were found to have higher PSA densities and were more likely to be upgraded at RP. Multivariate survival analysis also predicted fewer biochemical recurrence events over time in men with concordant Pbx tissue and RP specimen of GS 6 vs. 6/7 or 7/7 (P = 0.0025) controlling for other relevant covariates.
CONCLUSIONS: GS discordance between Pbx tissue and RP specimens among prostate cancer patients initially diagnosed with either GS 6 or 7 adenocarcinoma of the prostate is substantial. This discordance has potential clinical significance in predicting oncologic outcomes. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19117774     DOI: 10.1016/j.urolonc.2008.09.030

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  11 in total

1.  Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database.

Authors:  Christopher J Kane; Ronald Im; Christopher L Amling; Joseph C Presti; William J Aronson; Martha K Terris; Stephen J Freedland
Journal:  Urology       Date:  2010-04-15       Impact factor: 2.649

2.  Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy.

Authors:  Carolina D'Elia; Maria Angela Cerruto; Antonio Cioffi; Giovanni Novella; Stefano Cavalleri; Walter Artibani
Journal:  Mol Clin Oncol       Date:  2014-08-05

3.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades.

Authors:  Jonathan I Epstein; Zhaoyong Feng; Bruce J Trock; Phillip M Pierorazio
Journal:  Eur Urol       Date:  2012-02-08       Impact factor: 20.096

4.  The diagnostic value of adiponectin multimers in healthy men undergoing screening for prostate cancer.

Authors:  Edward A Medina; Xiaoyu Shi; Marcia H Grayson; Donna P Ankerst; Carolina B Livi; Maria V Medina; Ian M Thompson; Robin J Leach
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-12-02       Impact factor: 4.254

5.  Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6.

Authors:  Hasmet Sarici; Onur Telli; Orhan Yigitbasi; Musa Ekici; Berat Cem Ozgur; Cem Nedim Yuceturk; Muzaffer Eroglu
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

6.  Higher prostate weight is inversely associated with Gleason score upgrading in radical prostatectomy specimens.

Authors:  Leonardo Oliveira Reis; Emerson Luis Zani; Leandro L L Freitas; Fernandes Denardi; Athanase Billis
Journal:  Adv Urol       Date:  2013-10-31

7.  Does the time from biopsy to radical prostatectomy affect Gleason score upgrading in patients with clinical t1c prostate cancer?

Authors:  Muzaffer Eroglu; Omer Gokhan Doluoglu; Hasmet Sarici; Onur Telli; Berat Cem Ozgur; Selen Bozkurt
Journal:  Korean J Urol       Date:  2014-06-16

8.  Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6.

Authors:  Glen Denmer R Santok; Ali Abdel Raheem; Lawrence Hc Kim; Kidon Chang; Trenton Gh Lum; Byung Ha Chung; Young Deuk Choi; Koon Ho Rha
Journal:  Investig Clin Urol       Date:  2017-02-15

9.  Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.

Authors:  Muammer Altok; Patricia Troncoso; Mary F Achim; Surena F Matin; Graciela N Gonzalez; John W Davis
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

10.  Does Protocol Make a Difference? Comparison of Two Prostate Cancer Active Surveillance Cohorts: A Non-protocol-based Follow-up and a Protocol-based Contemporary Follow-up.

Authors:  Inari Kalalahti; Hanna Vasarainen; Andrew M Erickson; Arttu Siipola; Kari A O Tikkinen; Antti Rannikko
Journal:  Eur Urol Open Sci       Date:  2021-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.